Selections from current literature: Pharmacological treatment of obesity

Family Practice

Volumn 15, Issue 1, 1998, Pages 88-93

  Connolly, Josephine ^a   Verni, Christina ^a   Trilling, Jeff ^a   Kelso, Elizabeth ^a   Shiesha, Sam ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE; SEROTONIN UPTAKE INHIBITOR;

CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HUMAN; OBESITY; PULMONARY HYPERTENSION; REVIEW;

APPETITE DEPRESSANTS; DRUG THERAPY, COMBINATION; FENFLURAMINE; HUMANS; HYPERTENSION, PULMONARY; OBESITY; PHENTERMINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031989159     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/15.1.88     Document Type: Article

References (21)

1. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pliannacol Hier 1992; 51: 581.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse ob gene and its human homologue. Nature 1994; 372: 425-432.
3. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 1996; 334: 292-295.
4. Clement K, Vaisse C, Manning BS et al. Genetic variation in the beta3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl J Med 1995; 333: 352-354.
5. Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: National Academy Press, 1995: 5.
6. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: (8672) 1142-1145.
7. Goldstein DS. Beneficial effects of modest weight loss. Int J Obesity 1992; 16: 397-415.
8. Brownell KD, Wadden TA. The heterogenecity of obesity: fitting treatments to individual. Behav Tlier 1991; 22: 153-177.
9. Wadden TA, Foster GD, Letizia KA, Müllen JL. Long-term effects of dieting on resting metabolic rate in obese outpatients. JAMA 1990; 264: 707-711.
10. The American Dietetic Association. Position of the American Dietetic Association on Weight Management. J Am Dietetic Assoc 1997; 1: 71-74.
11. Levitsky DA, Troiano R. Metabolic consequences of fenfluramine for the control of body weight. AmJ Clin Nutrition 1992; 55: 167S-172S.
12. Editorial Staff. Dexfenfluramine for obesity. Med Letter 1996; 38: 64-65.
13. Manson JE, Faich GA. Pharmacotherapy for obesity: Do the benefits outweigh the risks? [editorial]). New EnglJ Med 1996; 335: 659-660.
14. Bremer JM, Russell S, Lintott CJ. Dexfenfluramine reduces cardiovascular risk factors. IntJ Obesity 1994; 18: 199-205.
15. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabetic Med 1992; 9: 341-343.
16. Stewart GO, Stein GR, Davis TM, Findlater P. Dexfenfluramine in type E diabetes: effect on weight and diabetes control. Med J Australia 1993; 158: 167-169.
17. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study VI. Clin Phannacol Tlier 1992; 51: 619-633.
18. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-1915.
19. Bjorntorp P. Neuroendocrine abnormalities in human obesity. Metabolism 1995; 44: 38-41.
20. Wurtman JJ, Wurtman RJ, Tsay MS et al. D-fenfluramine selectively suppresses carbohydrate snacking by obese subjects. Int J Eating Disorders 1985; 4: 89-99.
21. Toornvliet AC, Fiji H, Hopman E, Elte-de Wever BM, Meinders AE. Serotoninergic drug-induced weight loss in carbohydrate craving obese patients. IntJ Obesity Related Metab Disorders 1996; 20: 917-920.